ABSTRACT
Vitiligo affects about 1%–4% of the world's population and presents as milky-white macules involving the skin and/or mucosa. It does not cause much physical impairment but causes impairment in mental health and quality of life (QoL) due to its disfiguring appearance, causing discrimination and segregation in certain cultures. Vitiligo affects physical, social, psychological, and occupational aspects of QoL. Dermatology-specific questionnaires are available for measuring the QoL in vitiligo patients. An empathetic and supportive doctor-patient relationship, information regarding the disease, prompt treatment, social support, psychotherapeutic interventions, and psychotropic therapy help the patient live with vitiligo and manage its associated psychosocial and psychiatric comorbidity.
